Who owns eFFECTOR Therapeutics?

eFFECTOR Therapeutics is formerly owned by Abingworth, through Abingworth Bioventures VI, since 2013.

When did Abingworth acquire eFFECTOR Therapeutics?

Abingworth acquired eFFECTOR Therapeutics in 2013 and exited after 8 years.

Has eFFECTOR Therapeutics been sold?

Yes. eFFECTOR Therapeutics was exited in 2021 via IPO.

Home/Companies/Biotech/eFFECTOR Therapeutics

eFFECTOR Therapeutics

Biotech·

US·Exited 2021·Held 8yr

eFFECTOR Therapeutics is a biotech company, headquartered in US.

Entry

2013

Hold

8yr

Exit

2021

Est. EV

–

Investor

Abingworth

Key facts

HQUS

SectorBiotech

StatusAcquired

US oncology biotechnology company developing selective translation regulators; it became publicly listed in 2021 through a merger with the…Read full notes

See the full ownership history.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Full fund context: vintage, strategy, region

Exit details: type, year, MOIC (buyer on Pro)

Start free

Already a member? Sign in

More from Abingworth Bioventures VI

Other portfolio companies in the same fund.

More PE-backed in Biotech

Comparable biotech deals from other GPs.

AdBio PartnersBelgium

Last updated May 2026 · Sourced from public filings